Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.38 |
| ▸ | DRD3 | P35462 | 7/20 | 0.38 |
| ▸ | DRD4 | P21917 | 6/20 | 0.38 |
| ▸ | DRD1 | P21728 | 5/20 | 0.38 |
| ▸ | DRD5 | P21918 | 5/20 | 0.38 |
| ▸ | HTR1D | P28221 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296439 | 0.76 | SMN1; SMN2 (0.47) | — | |
| SCHEMBL588855 | 0.75 | HSD11B1 (0.40) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL17052944 | 0.74 | MPI (0.42) | AOC3ALDH1A1 | |
| SCHEMBL23535040 | 0.70 | CXCR2 (0.36) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL31381607 | 0.70 | ESR2 (0.38) | CA1CA2 | |
| SCHEMBL31274179 | 0.68 | ALDH1A1 (0.33) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL5001561 | 0.68 | MCHR1 (0.38) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL17292454 | 0.67 | DRD2 (0.41) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL31180674 | 0.67 | KCNH2 (0.35) | AOC3ALDH1A1 | |
| SCHEMBL5178160 | 0.66 | CA1 (0.56) | DRD2DRD3DRD4DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424865-B1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INT (DE) | 2017-01-18 | — | — | EP | disclosed |
| EP-2424865-B1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INT (DE) | 2017-01-18 | — | — | EP | disclosed |
| EP-2687525-B1 | CYCLIC INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INT (DE) | 2015-09-23 | — | — | EP | disclosed |
| EP-2687525-B1 | CYCLIC INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INT (DE) | 2015-09-23 | — | — | EP | disclosed |
| EP-2324017-B1 | INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INT (DE) | 2014-12-31 | — | — | EP | disclosed |
| EP-2324017-B1 | INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INT (DE) | 2014-12-31 | — | — | EP | disclosed |
| US-8846668-B2 | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846668-B2 | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846668-B2 | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2183228-B1 | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20100331320-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2010127237-A2 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | WO | disclosed |
| EP-2183228-A1 | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2010010157-A2 | INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011314-A1 | CYCLIC INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011314-A1 | CYCLIC INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009134400-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134400-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331320-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | DRD2 2742/4885DRD3 2832/4885DRD4 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.